{"disease":{"id":"metastatic-renal-cell-carcinoma-mrcc","name":"metastatic renal cell carcinoma mrcc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05287464","title":"International Multicentric Study ARON-1","phase":"","overall_status":"RECRUITING","enrollment_count":1220,"lead_sponsor_name":"Hospital of Macerata","has_results":false},{"nct_id":"NCT02184416","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","phase":"","overall_status":"COMPLETED","enrollment_count":554,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07233668","title":"Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04175262","title":"Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04115189","title":"A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01514448","title":"Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}